Published in Proc Natl Acad Sci U S A on August 16, 2010
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers (Basel) (2012) 2.35
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A (2012) 2.04
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α. Structure (2011) 1.48
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev (2012) 1.32
PI3K and STAT3: a new alliance. Cancer Discov (2011) 1.31
A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2010) 1.23
Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med (2014) 1.20
Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One (2012) 1.06
Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul (2012) 1.05
A beta version of life: p110β takes center stage. Oncotarget (2010) 1.01
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem (2012) 0.94
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K). Proc Natl Acad Sci U S A (2014) 0.90
Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. FEBS Lett (2012) 0.89
Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ (2012) 0.89
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure. J Biol Chem (2011) 0.82
BMP2-induced chemotaxis requires PI3K p55γ/p110α-dependent phosphatidylinositol (3,4,5)-triphosphate production and LL5β recruitment at the cytocortex. BMC Biol (2014) 0.82
The structural basis of PI3K cancer mutations: from mechanism to therapy. Cancer Res (2014) 0.81
Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis. Biochem J (2012) 0.81
Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation. Oncogene (2015) 0.79
The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience (2015) 0.77
Identification of mutations in distinct regions of p85 alpha in urothelial cancer. PLoS One (2013) 0.77
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics (2016) 0.77
PI3King the right partner: unique interactions and signaling by p110β. Postdoc J (2015) 0.76
Significance of p85 expression as a prognostic factor for patients with breast cancer. Oncol Lett (2014) 0.75
Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design. Protein Sci (2014) 0.75
Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model. Biosci Rep (2017) 0.75
Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β. Oncotarget (2017) 0.75
Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation. J Mol Model (2014) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Characteristics of two new avian tumor virus subgroups. Virology (1969) 3.81
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Oncogenic PI3K and its role in cancer. Curr Opin Oncol (2006) 3.61
Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res (2005) 3.19
The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A (1998) 2.99
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85
Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev (1990) 2.46
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J (1998) 2.13
Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem (1995) 2.06
Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J Biol Chem (1998) 1.97
The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem (2000) 1.71
Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem (2005) 1.57
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A (2009) 1.46
Oncogenic signaling of class I PI3K isoforms. Oncogene (2007) 1.43
Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35
Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia (2002) 1.20
Construction and characterization of a replication-competent retroviral shuttle vector plasmid. J Virol (2002) 1.03
The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch. Arch Biochem Biophys (2004) 0.97
A new non-radioactive method for IL-2 bioassay. Mol Cells (2000) 0.97
Integration of avian sarcoma virus DNA in chicken cells. Virology (1981) 0.93
The structure of p85ni in class IA phosphoinositide 3-kinase exhibits interdomain disorder. Biochemistry (2010) 0.83
A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation. J Biol Chem (2001) 0.82
Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: effects on catalytic subunit binding and holoenzyme function. Biol Chem (2006) 0.80
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2006) 2.91
Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci U S A (2006) 2.70
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A (2004) 2.19
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A (2002) 2.11
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72
Therapeutic Targeting of Myc. Genes Cancer (2010) 1.68
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle (2012) 1.67
Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res (2005) 1.59
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther (2011) 1.41
Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer (2009) 1.36
PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev (2009) 1.32
A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci U S A (2003) 1.30
100 years of Rous sarcoma virus. J Exp Med (2011) 1.24
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol (2005) 1.20
Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17
PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol (2010) 1.16
Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle (2005) 1.16
Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene (2003) 1.16
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14
Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle (2010) 1.11
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett (2009) 1.11
Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc Natl Acad Sci U S A (2003) 1.09
Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer (2013) 1.09
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci U S A (2004) 1.01
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
MafA has strong cell transforming ability but is a weak transactivator. Oncogene (2003) 0.96
Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene (2003) 0.96
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep (2008) 0.95
[Ru(bpy)2(L)]Cl2: luminescent metal complexes that bind DNA base mismatches. Inorg Chem (2004) 0.94
Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes. Oncogene (2002) 0.94
An essential role for protein synthesis in oncogenic cellular transformation. Oncogene (2004) 0.94
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. J Am Chem Soc (2009) 0.93
Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. J Am Chem Soc (2011) 0.93
Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function. Mol Pharmacol (2009) 0.90
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett (2007) 0.90
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget (2010) 0.88
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides. J Am Chem Soc (2004) 0.88
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Mol Ther Nucleic Acids (2013) 0.87
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87
Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. Int J Cancer (2009) 0.87
Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res (2009) 0.86
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. Int J Cancer (2010) 0.84
Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle (2011) 0.83
Progress in breast cancer research. Proc Natl Acad Sci U S A (2012) 0.82
Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle (2011) 0.81
Cell entry by non-enveloped viruses. Curr Top Microbiol Immunol (2010) 0.81
Biochemical and biological characterization of tumor-associated mutations of p110alpha. Methods Enzymol (2008) 0.81
The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene (2003) 0.80
Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene (2003) 0.80
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs (2014) 0.80
MYCNOS functions as an antisense RNA regulating MYCN. RNA Biol (2015) 0.79
v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene (2004) 0.77
Akt demoted in glioblastoma. Sci Signal (2009) 0.76
The classic: integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts: (RNA tumor viruses/reassociation kinetics/duck cells). 1973. Clin Orthop Relat Res (2008) 0.75
RICHARD BING: 12 OCTOBER 1909 - 8 NOVEMBER 2010. Proc Am Philos Soc (2014) 0.75